ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes.ARA 290 has been shown to be effective in the reduction of inflammation and activation of the healing process in a wide variety of preclinical models as well as in patients.

 With respect to diabetes, substantial recent work has shown that rhEPO can improve the diabetic state in animal models . However, in addition to interacting with the innate repair receptor in a paracrine/autocrine manner, EPO also functions as a circulating hormone via its interaction with the EPO receptor homodimer that mediates hematopoiesis.